Salmeterol/fluticasone propionate (50/250 μg) combination is superior to double dose fluticasone (500 μg) for the treatment of symptomatic moderate asthma: A prospective, double-blind trial

Swiss Medical Weekly

Volumn 134, Issue 3-4, 2004, Pages 50-58

  Bergmann, Karl Christian ^a   Lindemann, L ^b   Braun, R ^b   Steinkamp, G ^c  

^a Allergie und Asthma Klinik   (Germany)

^b Clinical Research ^*

^c Clinical Infection Research   (Germany)

Author keywords

Asthma; Fluticasone; Inhaled corticosteroids; Lung function; Quality of life; Salmeterol; Treatment

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; SALMETEROL XINAFOATE; THEOPHYLLINE;

ADULT; ARTICLE; ASTHMA; CANDIDIASIS; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY POWDER; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; HEART ARRHYTHMIA; HUMAN; INHALER; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SPEECH DISORDER; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0942298705     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. National Heart, Lung, and Blood Institute, National Institutes of Health. Internationaler Konsensus-Bericht zur Diagnose und Behandlung des Asthma bronchiale. Pneumologie 1993;47:245-88.
2. Nelson HS. Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J Allergy Clin Immunol 2001;107:398-416.
3. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24.
4. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.
5. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
6. Ind PW, dal Negro R, Colman NC, Fletcher CP, Browning D, James MH. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 2003;97:555-62.
7. Wettengel R, Berdel D, Hofmann D, Krause J, Kroegel C, Kroidl RF, et al. Empfehlungen zur Asthmatherapie bei Kindern und Erwachsenen. Pneumologie 1998;52:591-601.
8. Quanjer PH. Standardized lung function testing. Report Working Party "Standardization of Lung Function Tests", European Community for Coal and Steel. Bull Europ Physiopathol Respir 1983;19:1-95.
9. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
10. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-7.
11. Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert Panel Report. J Allergy Clin Immunol 1991;88:425-534.
12. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368-73.
13. Heyneman CA, Crafts R, Holland J, Arnold AD. Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control. Ann Pharmacother 2002;36:1944-9.
14. Kemp JP, DeGraff ACJ, Pearlman DS, Wang Y, Arledge TE, Welch MB, et al. A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine. J Allergy Clin Immunol 1999;104:1189-97.
15. Sue-Chu M, Wallin A, Wilson S, Ward J, Sandström T, Djukanovic R, et al. Bronchial biopsy study in asthmatics treated with low and high dose fluticasone propionate (FP) compared to low dose FP combined with salmeterol. Eur Respir J 1999;14[Suppl 30]:S124.
16. Baraniuk JN, Ali M, Brody D, Maniscalco J, Gaumond E, Fitzgerald T, et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997;155:704-10.
17. Rudiger J, Bihl MB, Cornelius BC, Block LH, Johnson M, Perrechoud AP, et al. Addition of beta-2-agonists to glucocorticoid treatment augments glucucoticoid action via transcription factor C/EBPAlpha [B88]. Am J Respir Crit Care Med 2000;161(No. 3):1.
18. Tan KS, Grove A, McLean A, Gnosspelius Y, Hall IP, Lipworth BJ. Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 1997;156:28-35.
19. Anenden V, Egemba G, Kessel B, Johnson M, Costello J, Kilfeather S. Salmeterol facilitation of fluticasone-induced apoptosis in eosinophils of asthmatics pre- and post-antigen challenge. Eur Respir J 1998;12[28 (Suppl.)]:1107.
20. Korn SH, Wouters EF, Wesseling G, Arends JW, Thunnissen FB. Interaction between glucocorticoids and beta-2-agonists: alpha and beta glucocorticoid-receptor mRNA expression in human bronchial epithelial cells. Biochem Pharmacol 1998;56:1561-9.